Sign In
Buy LLY
$1,116.11
-5.06 (-0.451%)
At Close: Aug 04, 2026
Lilly Targets Vaccines With $3.8 Billion Acquisition Push
01:17pm, Tuesday, 26'th May 2026
Eli Lilly (LLY) is stepping back into infectious diseases with a three-deal vaccine push worth as much as $3.8 billion, giving investors another signal that the
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms
12:04pm, Tuesday, 26'th May 2026
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, a
Lilly Gets Back Into the Vaccine Business With New Deals
10:44am, Tuesday, 26'th May 2026
Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 26'th May 2026
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
09:51am, Tuesday, 26'th May 2026
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
Eli Lilly Goes On A $3.83 Billion Acquisition Spree. Where's It Pushing Now?
09:22am, Tuesday, 26'th May 2026
Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.
If Viking Therapeutics Is Acquired, Here’s Who Wins
08:50am, Tuesday, 26'th May 2026
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with a
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms
08:03am, Tuesday, 26'th May 2026
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in...
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
07:50am, Tuesday, 26'th May 2026
The deals are part of Eli Lilly's effort to expand into infectious disease research and development. Shares edged higher in premarket trading on the news.
First Look: Oil Slides on Iran Talks; Lilly M&A Ferrari's EV Debut
07:40am, Tuesday, 26'th May 2026
Stock News Oil drops on Iran peace signals: Crude fell 6â7% as President Trump said talks to reopen the Strait of Hormuz are âproceeding nicely,â while JP
Lilly announces three acquisitions to build infectious disease portfolio
06:45am, Tuesday, 26'th May 2026
Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or
Lilly Agrees to Buys Trio of Vaccine Developers
06:35am, Tuesday, 26'th May 2026
The weight-loss drug market leader is renewing a focus on infectious-disease prevention.
Eli Lilly weight loss drug data supports long-term obesity market position, says UBS
02:48pm, Monday, 25'th May 2026
Eli Lilly and Co (NYSE:LLY) last week reported late-stage weight loss data for retatrutide, which UBS analysts highlighted showed “solid strong weight loss efficacy” and were broadly in line with
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
10:46am, Monday, 25'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its p
